[197 Pages Report] The Renal Denervation Devices Market size was estimated at USD 236.29 million in 2023 and expected to reach USD 266.44 million in 2024, at a CAGR 13.68% to reach USD 579.85 million by 2030.
Renal denervation devices are medical tools that provide minimally invasive therapy for patients suffering from drug-resistant hypertension or high blood pressure that do not respond adequately to conventional pharmacological therapies. These devices offer an alternative solution by targeting the overactive sympathetic nerves surrounding the renal arteries, which play a crucial role in regulating blood pressure and contribute to the development of hypertension. The increasing prevalence of resistant hypertension among the global population due to lifestyle changes, rising awareness about the benefits of renal denervation procedures over conventional drug therapies, and the growing geriatric population are driving the renal denervation devices market growth. However, the high cost of renal denervation devices, associated procedures, and several stringent regulatory frameworks may hamper market growth. Technological advancements in device design and procedural techniques have improved efficacy and safety profiles for renal denervation treatments, which is expected to create a lucrative market opportunity.
The Americas has a significant landscape in the renal denervation devices market due to a high prevalence of hypertension among its population and substantial investments in research for novel therapies. Advancements in technology and growing awareness about innovative treatment options amongst healthcare professionals have fueled demand for these devices. The EU shows significant potential for market growth owing to increased awareness about renal denervation therapy and favorable reimbursement policies across countries. Collaborative efforts on hypertension prevention and control have accelerated R&D initiatives in this domain. The MEA region holds promising opportunities for renal denervation devices due to a rising incidence of hypertension coupled with lifestyle changes and urbanization. In the APAC region, government funding and initiatives for hypertension research resulted in a growing number of clinical trials and patent filings. Robust healthcare infrastructure, a strong focus on technological advancements, increased awareness about hypertension management, and improved healthcare facilities have contributed to the region's renal denervation devices market growth.
Micro-infusion-based renal denervation involves delivering small doses of anti-hypertensive drugs directly into the periarterial space surrounding the renal arteries. This targeted approach minimizes systemic side effects and improves drug efficacy. Pharmacologic ablation involves chemically destroying overactive renal nerves using neurotoxic agents such as alcohol or guanethidine. This technique is preferred when radiofrequency or ultrasound-based approaches are not feasible due to anatomical complexities or contraindications. Radiofrequency-based renal denervation involves applying controlled electrical energy to destroy targeted renal nerves. This method is preferred for its precision, safety, and effectiveness in reducing blood pressure. Ultrasound-based renal denervation uses high-frequency sound waves to generate localized heat that disrupts overactive renal nerves. This non-invasive technique makes it attractive for patients with contraindications or sensitivities to other methods.
Catheters are the primary device used in renal denervation procedures to deliver radiofrequency energy to ablate or modify nerves responsible for hypertension. They are primarily used for their minimally invasive nature and precision in targeting specific nerves. Multi-electrode catheters have multiple electrodes on the tip that enable simultaneous ablation of multiple nerve sites, reducing procedure time and potentially increasing efficacy. Nerve-modifying agents are pharmaceuticals that work alongside renal denervation devices to enhance procedural outcomes. These agents may improve overall patient response or minimize potential complications arising from the procedure. An RF (Radiofrequency) generator is an essential device used in renal denervation procedures for providing controlled energy to catheters to ablate nerves. Single electrode catheters feature a single electrode at the tip and are used for sequential ablation of nerve sites. These catheters offer greater precision in targeting specific nerves but may require longer procedures than multi-electrode variants.
Renal denervation devices have emerged as an effective treatment for diabetic patients suffering from hypertension and nephropathy. These devices modulate the overactive sympathetic nervous system responsible for worsening diabetic complications. Heart failure patients experience high sympathetic activity, leading to increased blood pressure and fluid overload factors contributing to progressive kidney damage. Renal denervation therapy can effectively reduce sympathetic hyperactivity in these patients, improving cardiac function and overall quality of life. In hypertension, renal denervation helps lower blood pressure by disrupting the renal sympathetic nerves, reducing their influence on blood pressure regulation. Renal denervation devices are being explored as a potential treatment option for chronic kidney disease (CKD) patients who often suffer from hypertension and diabetic complications. The therapy's ability to modulate the sympathetic nervous system may help slow CKD progression and alleviate symptoms associated with kidney dysfunction.
Ambulatory care centers (ACCs) are outpatient facilities that provide various medical services, including diagnosis and treatment for kidney-related diseases, and offer renal denervation devices to manage patients with hypertension. ACCs prefer minimally invasive and cost-effective solutions to ensure patient safety and comfort while maximizing operational efficiency. Diagnostic centers and hospitals are crucial in managing hypertension through early detection and intervention. With a growing global prevalence of uncontrolled hypertension and drug-resistant cases, these institutions require advanced renal denervation devices for optimal patient outcomes. Hospitals prioritize ease of use, adaptability with existing equipment, and robust clinical data support when selecting renal denervation devices. Research institutions and academic centers are at the forefront of hypertension management, developing novel therapies and devices for renal denervation. These organizations focus on cutting-edge technology with strong clinical evidence to support future advancements in the field.
The market dynamics represent an ever-changing landscape of the Renal Denervation Devices Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Renal Denervation Devices Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Renal Denervation Devices Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Renal Denervation Devices Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Renal Denervation Devices Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Renal Denervation Devices Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Renal Denervation Devices Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Renal Denervation Devices Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Renal Denervation Devices Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Renal Denervation Devices Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Renal Denervation Devices Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Renal Denervation Devices Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Renal Denervation Devices Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. and Otsuka Medical Devices Co., Ltd., its parent company, have announced the FDA approval of their Paradise Ultrasound Renal Denervation System for the treatment of hypertension. The Paradise System is designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, thus reducing hypertensive overactivity. [Published On: 2023-11-07]
FDA Approves Verve Medical’s IDE Renal Pelvic Denervation Trial
Verve Medical, Inc. has received an Investigational Device Exemption from the U.S. Food and Drug Administration ( FDA) for its renal denervation trial. The trial aims to estimate the safety and efficacy of the procedure by testing 300 patients. This pivotal trial by Verve is a 2:1 randomized, double-blinded, sham-controlled study, and it has the potential to benefit over 1 billion people worldwide who suffer from uncontrolled hypertension. [Published On: 2023-07-12]
Korean Startup Kalos Gets USD 3.5 Million Grant to Develop Renal Denervation Device for hypertension Treatment
Kalos Medical received a grant of KRW 4.67 billion (approximately USD 3.5 million) to expedite the development of its renal denervation medical device and to participate in the 2023 Industrial Technology Innovation Project. This project aims to combine MNTek's biomedical sensor technology with KETI's electronic medical device control system to enhance the development of Kalos' renal denervation medical device. [Published On: 2023-05-05]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Renal Denervation Devices Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Renal Denervation Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ablative Solutions, Inc., AngioDynamics, Inc., Aria CV, Inc., AtriCure, Inc., Bio-Heart, Boston Scientific Corporation, Cardinal Health, Inc., Kalos Medical, Medtronic PLC, Mercator MedSystems, Inc., Otsuka Holdings Co., Ltd., Shanghai Meiliweiye Medical Technology Co., Ltd., SoniVie, Symap Medical, Ltd., Symple Surgical, Inc., and Terumo Corporation.
This research report categorizes the Renal Denervation Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Technology
- Micro-Infusion-Based
- Pharmacologic Ablation
- Radiofrequency-Based
- Ultrasound-Based
- Products
- Catheters
- Multi Electrode Catheter
- Single Electrode Catheter
- Nerve Modifying Agents
- RF Generator
- Catheters
- Disease Application
- Diabetes
- Heart Failure
- Hypertension
- Renal Failure
- End-User
- Ambulatory Care Centers
- Diagnostic Centers & Hospitals
- Research & Academia
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Renal Denervation Devices Market, by Technology
- Renal Denervation Devices Market, by Products
- Renal Denervation Devices Market, by Disease Application
- Renal Denervation Devices Market, by End-User
- Americas Renal Denervation Devices Market
- Asia-Pacific Renal Denervation Devices Market
- Europe, Middle East & Africa Renal Denervation Devices Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 24]
- List of Tables [Total: 468]
- List of Companies Mentioned [Total: 17]
Renal denervation devices or solutions reduce the activity in the renal nerves of the kidneys, thereby lowering blood pressure. How do they do that? Using a catheter, of course! The catheter sends ultrasound or radiofrequency energy to the blood vessels (commonly known as renal arteries), supplying blood to the kidneys. This energy reduces nerve activity without damaging the nerves, and the reduction in nerve activity can be seen as a drop in blood pressure. While simple in theory, renal degeneration devices have proved indispensable in treating hypertension. Moreover, scientists have also uncovered their potential in managing heart failure, diabetes, and chronic renal failure. The additional advantage of renal denervation devices is that they are minimally invasive!
Given the valuable role of renal denervation devices in improving the health status of hypertension patients, the field of renal denervation devices is undoubtedly ripe with favorable regulatory approvals. In November 2023, the FDA approved the first renal denervation device to treat adults with hypertension that cannot be adequately controlled with lifestyle changes or medications.
Government grants are lighting the spark of innovations in developing renal denervation devices, and MedTech's active involvement has electrified the scene with constant breakthroughs. In December 2023, Medtronic announced the launch of its Symplicity Spyral renal denervation system (RDN) for treating high blood pressure.
Scientists and researchers have just touched the tip of the iceberg of the endless possibilities of renal denervation devices. As biotechnology, research, and medical technology advance, new application areas in the treatment of renal and cardiovascular conditions will soon be uncovered.
The primary goal of Renal Denervation Devices is to treat hypertension or high blood pressure. The latest RDN devices work based on long and short electrical pulses that target renal arteries' nerve tissues. The electrical pulses help inhibit the production of hormones that cause high blood pressure. This technology has proved very promising, and many countries across the globe have started using these devices to treat hypertension.
The latest advancement in RDN technology is the advent of radiofrequency-based RDN devices. Radiofrequency ablation technology is a non-surgical method that uses heat energy to destroy the targeted cells—the new radiofrequency-based RDN devices provide high-precision renal artery ablation, which helps reduce potential collateral damage in the surrounding tissue.
The traditional surgical procedure for hypertension treatment involves the removal of the renal artery. This method is invasive and may cause damage to the renal artery and surrounding tissue. However, we are witnessing the introduction of new alternative technologies, such as ultrasound-based RDN devices. The non-invasive Ultrasound-based RDN devices employ high-energy focused ultrasound waves to target and ablate renal artery nerves. This technology provides better precision, reduces potential collateral damage, and eliminates the need for incisions.
Another revolution in renal denervation devices is integrating artificial intelligence (AI). The integration of AI in RDN devices has boosted their efficacy, providing a safer and more effective treatment option for hypertension patients.
AI helps healthcare professionals identify blood pressure patterns and personalizes treatments based on these patterns. Further, AI-assisted RDN devices provide real-time imaging, helping healthcare professionals visualize the treatment area and monitor potential concerns.
The technological advancements in Renal Denervation Devices have opened new horizons in the healthcare industry. The development of alternative technologies, such as ultrasound-based devices, shows promise in providing minimally invasive treatments, while AI integration enhances precision and safety for hypertension patients. These revolutionary changes have significantly improved the healthcare sector's ability to treat hypertension and other cardiovascular diseases.
- How big is the Renal Denervation Devices Market?
- What is the Renal Denervation Devices Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?